

# TheMARK

## GlycoMark Updates for Healthcare Professionals Caring for Patients with Diabetes

DIABETES MANAGEMENT

Issue 11 - August/September 2018

### The GlycoMark Test and Clinical Perspectives from a Diabetes Educator

Dear GlycoMark Subscriber,

In our August/September The MARK newsletter, we would like to share excerpts from our recent interview with a Nationally Acclaimed Diabetes Educator and prolific author on diabetes, Gary Scheiner, Owner and Clinical Director at Integrated Diabetes Services.



**Gary Scheiner, MS, CDE**  
Owner and Clinical Director  
Integrated Diabetes Services, LLC  
Wynnewood, PA

#### How do you currently use the GlycoMark test?

After we gain control of premeal glucose levels, we focus on postprandial control. Unfortunately, you reach a glass ceiling just looking at fasting and premeal glucose. A low GlycoMark test lets us know we need to address postmeal issues.

Most patients with Type 2 diabetes lose first-phase insulin release, and that's going to result in abnormal postprandial glucose. If the GlycoMark is unusually low, then I will likely intensify therapy.

Even if someone wears a professional CGM for a week and shows good control between meals, it's worth doing the GlycoMark test a few times per year to gain more data, which can then be used to help determine if the chosen therapy is still working.

[Read the Full Interview](#)

---

Join Us! Upcoming Sponsored Events:

**Exhibiting - Cardiometabolic Risk Summit**  
September 14-16, 2018 - San Antonio, TX

**Exhibiting - American Association of Clinical Endocrinologists (AACE)  
11th Annual Meeting New Jersey Chapter**  
October 6, 2018 - Princeton, NJ

[Click here](#) to schedule time to meet with the GlycoMark team.

---

## How to Order the GlycoMark Test:

The GlycoMark test is reimbursed by most federal, state and private payers (CPT Code 84378) and available through various national and regional laboratories, and as a test kit for use on most automated chemistry instruments. [Click Here](#) for more information!

---

The Mark newsletter is distributed to healthcare professionals that treat and manage patients with diabetes, and contains the latest updates and important references for the GlycoMark test. This is a complimentary publication provided through the generous support of GlycoMark, Inc.

The information contained herein is not medical, diagnostic or treatment advice for any particular patient. Physicians should use their clinical judgment and experience when deciding how to diagnose and treat patients and in the use of the GlycoMark test in the treatment of the patient. Please refer to the GlycoMark product insert for more information.

The GlycoMark test is FDA cleared for professional use to provide quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The GlycoMark test is intended for intermediate-term monitoring of glycemic control in patients with diabetes. It is not intended to be used to identify patients that will experience complications of diabetes or the likelihood of experiencing complications.

For full GlycoMark prescribing information please [see our package insert](#).

Subsequent to incorporating the GlycoMark test into clinical practice, the physician became a paid clinical consultant of GlycoMark.

GlycoMark is a registered trademark of GlycoMark, Inc. © 2018 GlycoMark, Inc. All Rights Reserved. M-63-1A



805 Third Avenue, 17th Floor, New York, NY 10022  
1-888-744-0221 - [info@glycomark.com](mailto:info@glycomark.com) - [www.glycomark.com](http://www.glycomark.com)